Combination Therapy in Pulmonary Arterial Hypertension: Gleaning a Practical Approach from the Randomized Trials.

Area of Science:

• Cardiology
• Pulmonary Medicine
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) treatment has historically been limited.
• The evolution of PAH therapy now includes multiple drug options and administration routes.

Purpose of the Study:

• To review the evidence supporting combination therapy in PAH.
• To discuss the current landscape and future directions of PAH treatment strategies.

Main Methods:

• Analysis of data from key clinical trials including SERIPHIN, AMBITION, and GRIPHON.
• Review of emerging findings from FREEDOM-EV.

Main Results:

• Randomized clinical trials confirm the validity of combination therapy for PAH.
• Combined therapy significantly reduces disease progression and shows promise for survival benefit.
• Current FDA-approved agents primarily focus on vasodilation, with limited impact on arteriopathy progression.

Conclusions:

• Combination therapy is an established and effective strategy for managing PAH.
• Future research should focus on treatments that halt progression and reverse pulmonary arteriolar obstruction.
• A trend towards multi-agent treatment for PAH is evident and likely to continue.